CRIC研究:CKD患者血浆铁调素水平与心血管、肾脏及代谢结局的关联
在3826例慢性肾脏病(CKD)患者中,血浆铁调素中位数为43 ng/mL;最高三分位与肾脏结局和动脉粥样硬化事件风险增加独立相关,最低三分位与全因和心血管死亡风险增加相关,而铁调素与心衰或糖尿病前期/糖尿病无关联。
要点
- 铁调素最高三分位者肾脏结局风险增加19%,动脉粥样硬化事件风险增加34%。
- 铁调素最低三分位与全因和心血管死亡风险增加相关。
- 铁调素水平与心衰或糖尿病前期/糖尿病发病无显著关联。
核心结论
- 血浆铁调素过低或过高均与CKD患者不良临床结局相关。
研究设计与样本
- 前瞻性队列研究,纳入慢性肾功能不全队列(CRIC)中3826例CKD患者。
主要发现
- 血浆铁调素中位数(四分位距)为43(22,77)ng/mL。
- 最高三分位铁调素与肾脏结局风险增加独立相关(HR 1.19;95%CI 1.09,1.30)。
- 最高三分位铁调素与动脉粥样硬化事件风险增加独立相关(HR 1.34;95%CI 1.09,1.64)。
- 最低三分位铁调素与全因和心血管死亡风险增加相关。
- 铁调素与心衰或糖尿病前期/糖尿病发病无关联。
临床怎么用
- 在CKD患者中可关注血浆铁调素水平,低值或高值均提示不良结局风险,但尚不能作为独立治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Abnormal iron homeostasis plays a critical role in extra-hematopoietic disorders. The relationship of hepcidin, the master iron regulator, to clinical outcomes, has not been characterized in a large cohort of chronic kidney disease (CKD). METHODS: To determine if plasma hepcidin level predicts cardiovascular (CV), kidney, and metabolic outcomes in patients with CKD, we studied 3826 patients enrolled in the Chronic Renal Insufficiency Cohort (CRIC) study. Hazard ratios for hepcidin tertiles were estimated from Cox Proportional Hazards regression for primary outcomes of incident heart failure (HF), end stage kidney disease (kidney failure) or halving of the estimated glomerular filtration rate (eGFR), and new onset diabetes or prediabetes. Secondary outcomes included atherosclerotic events and all-cause and CV mortality. RESULTS: The median and interquartile range of plasma hepcidin level was 43 (22, 77) ng/mL. Higher plasma hepcidin levels were associated with older age, male sex, non-Hispanic Black race, diabetes, lower eGFR, higher albuminuria, increased plasma levels of iron indices, C-terminal fibroblast growth factor 23, and markers of inflammation (high-sensitivity C-reactive protein and interleukin-6). We found no association between plasma hepcidin level and the risk for incident HF or prediabetes/diabetes. However, compared to the middle tertile, the highest hepcidin tertile was independently associated with increased risk for kidney outcomes (hazard ratio 1.19; 95% confidence interval 1.09, 1.30) and atherosclerotic events (hazard ratio 1.34; 95% confidence interval 1.09, 1.64), while the lowest hepcidin tertile was associated with increased risk for all-cause and CV mortality in fully adjusted multivariable models including iron indices and inflammation. CONCLUSION: Both low and high plasma levels of hepcidin are associated with adverse clinical outcomes.
引用
- Cho ME, Mehta RC, Greene T, et al. The Chronic Renal Insufficiency Cohort (CRIC) study measured hepcidin, cardiovascular, kidney and metabolic outcomes in chronic kidney disease. Kidney Int. 2026. PMID: 42901323. doi:10.1016/j.kint.2026.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。